Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006)
GLP-1 RAs may be effective adjuvants to RT in breast cancer, particularly for patients with diabetes. The dual benefit of tumor sensitization and protection of normal tissues offers a promising therapeutic avenue.
Authors
- Yasemin Şengün (ORCID: https://orcid.org/0000-0001-8289-1713)
- Eyüb Yaşar Akdemir (ORCID: https://orcid.org/0000-0002-6848-4289)
- Duygu Deniz Usta
- Şefika Dinçer
- Yıldız Güney (ORCID: https://orcid.org/0000-0003-2251-3571)
- Ece Atak (ORCID: https://orcid.org/0000-0001-9215-5664)
- Atiye Seda Yar Sağlam (ORCID: https://orcid.org/0000-0002-9201-8464)
- Elvan Anadol (ORCID: https://orcid.org/0000-0002-6029-7358)
- Özüm Atasoy (ORCID: https://orcid.org/0000-0001-5115-7815)
- Gülnur Take Kaplanoğlu (ORCID: https://orcid.org/0000-0002-3661-3488)
- Ahmet Sert (ORCID: https://orcid.org/0000-0002-1607-7569)
Institutions
- Van Yüzüncü Yıl Üniversitesi (TR)
- Giresun University (TR)
- Akdeniz University (TR)
- Memorial Ankara Hospital (TR)
- Miami Heart Research Institute (US)
- Miami Transplant Institute (US)
- Istanbul Medeniyet University (TR)
- Gazi University (TR)
Publication Details
- Journal
- Current Radiopharmaceuticals
- Published
- 2025-05-07
- DOI
- https://doi.org/10.2174/0118744710381356250429045716
- Citations
- 2
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.87